Direct Osteoblast Reprogramming via Gene Introduction

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for preparing osteoblasts for bone repair, such as using bone marrow cells or pluripotent stem cells, are invasive, inefficient, and carry risks of carcinogenesis and immunological rejection, with no direct conversion of somatic cells into osteoblasts available.

Innovation Solution

An in vitro method involving direct reprogramming of somatic cells, specifically fibroblasts, using a combination of bone-related genes like Runx2, Osterix, and Dlx5, and reprogramming-related genes like Oct4, c-Myc, and L-Myc, to induce osteoblast formation without conversion into pluripotent stem cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If bone marrow cells are used as osteoblasts for transplantation, then osteoblasts can be obtained for bone repair, but the collection process is highly invasive and cannot supply sufficient numbers of cells in some cases

Engineering Contradiction:
Improvenumber of osteoblastsVSAvoidinvasiveness of collection
Core Design Contradiction:
Quantity of substanceVSEase of operation

Solution Approach 1:

The invention extracts and utilizes reprogramming genes (Oct4, Sox2, Klf4, c-Myc) from the system of pluripotent stem cell generation, applying them directly to somatic cells to induce osteoblast differentiation without requiring actual stem cell transplantation or invasive bone marrow collection

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The invention introduces reprogramming genes as intermediaries that mediate the transformation of somatic cells into osteoblasts, serving as a molecular bridge that enables direct conversion without requiring invasive cell collection or prolonged culture

Inventive Principle:
Principle #24Intermediary (Mediator)

2Quantity of substance

If human embryonic stem cells are used to prepare osteoblasts, then a sufficient number of osteoblasts can be supplied without bone marrow collection, but there is a risk of tumorigenesis of residual ES cells after transplantation

Engineering Contradiction:
Improvenumber of osteoblastsVSAvoidrisk of tumorigenesis
Core Design Contradiction:
Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The invention extracts only the essential reprogramming genes (Oct4, Sox2, Klf4, c-Myc) from the complex pluripotent stem cell system, applying them directly to somatic cells to induce osteoblast differentiation, thereby eliminating the need for ES cell culture and the associated tumorigenesis risk

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The invention skips the intermediate pluripotent stem cell stage entirely, directly converting somatic cells to osteoblasts through gene introduction, thus avoiding the prolonged culture period and tumorigenesis risk associated with ES and iPS cell methods

Inventive Principle:
Principle #21Skipping (Rushing through)

3Quantity of substance

If iPS cells are used to prepare osteoblasts, then a sufficient number of osteoblasts can be supplied without bone marrow collection, but there is a risk of tumorigenesis of residual iPS cells after transplantation

Engineering Contradiction:
Improvenumber of osteoblastsVSAvoidrisk of tumorigenesis
Core Design Contradiction:
Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The invention extracts and utilizes the core reprogramming genes (Oct4, Sox2, Klf4, c-Myc) from the iPS cell generation process, applying them directly to induce osteoblast differentiation from somatic cells, thereby avoiding the need for iPS cell culture and associated risks

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The invention skips the iPS cell intermediate stage by directly introducing reprogramming genes into somatic cells to induce osteoblast differentiation, significantly reducing culture time and eliminating tumorigenesis risk

Inventive Principle:
Principle #21Skipping (Rushing through)

4Quantity of substance

If osteoblasts are prepared from pluripotent stem cells by differentiation induction, then osteoblasts can be obtained, but the methods require long-term culture and have risks of carcinogenesis

Engineering Contradiction:
Improvenumber of osteoblastsVSAvoidculture period
Core Design Contradiction:
Quantity of substanceVSLoss of time

Solution Approach 1:

The invention rushes through the differentiation process by directly introducing reprogramming genes (Oct4, Sox2, Klf4, c-Myc) into somatic cells to induce osteoblast formation, significantly shortening the culture period from months to weeks

Inventive Principle:
Principle #21Skipping (Rushing through)

Solution Approach 2:

The invention performs preliminary action by pre-introducing reprogramming genes into somatic cells before differentiation induction, priming the cells for rapid osteoblast conversion and reducing the overall culture time required

Inventive Principle:
Principle #10Preliminary action

5Quantity of substance

If osteoblasts are prepared from pluripotent stem cells by differentiation induction, then osteoblasts can be obtained, but there are risks of carcinogenesis

Engineering Contradiction:
Improvenumber of osteoblastsVSAvoidrisk of carcinogenesis
Core Design Contradiction:
Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The invention extracts only the necessary reprogramming genes (Oct4, Sox2, Klf4, c-Myc) from the pluripotent stem cell system and applies them directly to somatic cells for osteoblast induction, eliminating the need for prolonged pluripotent cell culture and associated carcinogenesis risks

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The invention skips the pluripotent stem cell stage entirely by directly converting somatic cells to osteoblasts through gene introduction, thereby avoiding the carcinogenesis risk associated with residual pluripotent cells

Inventive Principle:
Principle #21Skipping (Rushing through)

Data Source

PatentEP3026112B1Osteoblast and method for preparing same
Publication Date: 2022.09.21 KYOTO PREFECTURAL PUBLIC UNIV CORP
  • EP3026112B1 patent drawingFigure 1
  • EP3026112B1 patent drawingFigure 2
  • EP3026112B1 patent drawingFigure 3A

AI summary

The present invention relates to: a method of preparing an osteoblast from a somatic cell of a mammal, the method including introducing a bone-related gene or an expression product thereof and a reprogramming-related gene or an expression product thereof, or introducing a reprogramming-related gene or an expression product thereof independently into the somatic cell, the bone-related gene including at least one kind selected from the group consisting of Runx2 (R), Osterix (O) , and Dlx5 (D), the reprogramming-related gene including at least one kind selected from the group consisting of Oct family, c-Myc (M), L-Myc (L), Klf family, Lin-28, and Sox2; and an osteoblast prepared by the method.